Our Pricing

Wegovy vs Mounjaro UK: Which Weight Loss Injection Works Best?

When comparing Wegovy vs Mounjaro UK options, patients often ask which injectable delivers better weight loss results and represents better value. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) are MHRA-licensed prescription treatments that work by mimicking gut hormones to reduce appetite and improve blood sugar control, but they differ in mechanism, efficacy, and cost. This comprehensive comparison examines clinical trial data, real-world outcomes, side effect profiles, and UK pricing to help you make an informed choice with your prescriber.

How Wegovy vs Mounjaro UK Treatments Work Differently

The fundamental difference in the Wegovy vs Mounjaro UK comparison lies in their pharmacological mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics one gut hormone to suppress appetite and slow gastric emptying [1]. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that activates two hormone pathways simultaneously, potentially offering enhanced metabolic benefits [2].

In clinical practice, this dual-action mechanism means Mounjaro may deliver slightly greater weight reduction for some patients, though individual responses vary considerably. Both treatments require once-weekly subcutaneous injection and work best alongside a reduced-calorie diet and increased physical activity. The MHRA has licensed both medications for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [3].

Our superintendent pharmacist Tarun Kumar notes that the choice between these treatments should be guided by your prescriber's clinical assessment, considering your medical history, previous weight loss attempts, and tolerance to GLP-1 medications. Both require ongoing prescription monitoring and are not suitable for everyone.

Wegovy vs Mounjaro UK Clinical Trial Results: Which Delivers Greater Weight Loss?

When examining Wegovy vs Mounjaro UK efficacy data, the STEP clinical trial programme for semaglutide showed participants lost an average of 15% of their body weight over 68 weeks at the 2.4mg maintenance dose [1]. The SURPASS trials for tirzepatide demonstrated even more substantial results, with participants losing up to 22.5% of body weight at the highest 15mg dose over 72 weeks [2].

However, these impressive figures require important context. Not every patient achieves average results, and both medications show considerable individual variation. In the STEP 1 trial, approximately 86% of participants on Wegovy 2.4mg achieved at least 5% weight loss, whilst 69% achieved 10% or greater reduction [1]. The SURMOUNT-1 trial showed 91% of participants on Mounjaro 15mg achieved at least 5% weight loss, with 57% reaching 20% or more [2].

Real-world outcomes in UK clinical practice often differ from controlled trial conditions. Adherence, lifestyle modification commitment, and individual metabolic factors all influence results. Both treatments work progressively through dose escalation protocols that minimise gastrointestinal side effects whilst optimising weight reduction over several months.

Head-to-Head Wegovy vs Mounjaro UK Comparison Data

Direct comparison studies examining Wegovy vs Mounjaro UK outcomes are limited, but the SURPASS-2 trial included a semaglutide 1mg comparator arm against tirzepatide doses. Results showed tirzepatide 10mg and 15mg produced significantly greater weight loss than semaglutide 1mg, though this dose is lower than Wegovy's 2.4mg maintenance dose [4]. Ongoing trials are examining these medications at their approved weight management doses in head-to-head comparisons, which will provide more definitive guidance for UK prescribers.

Side Effects: Wegovy vs Mounjaro UK Tolerability Profiles

The side effect profiles in the Wegovy vs Mounjaro UK comparison are remarkably similar, as both medications work through related mechanisms. The most common adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation phases [1][2]. These gastrointestinal symptoms typically diminish over several weeks as your body adapts to the medication.

In clinical trials, approximately 5-7% of participants discontinued Wegovy due to adverse effects, whilst Mounjaro showed similar discontinuation rates of 4-7% depending on the dose [1][2]. Both medications carry warnings about potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans), pancreatitis risk, and gallbladder problems including gallstones.

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use either medication. Your prescriber will assess contraindications during your clinical consultation, and ongoing monitoring is essential throughout treatment. If you experience persistent severe abdominal pain, vision changes, or signs of pancreatitis, seek immediate medical attention.

Managing Side Effects with Wegovy vs Mounjaro UK Treatments

Successful management of side effects when comparing Wegovy vs Mounjaro UK options involves gradual dose escalation, eating smaller meals, avoiding high-fat foods, and staying well-hydrated. Our clinical team provides detailed guidance on minimising gastrointestinal symptoms whilst maximising treatment efficacy. Most patients find side effects manageable and temporary, though individual tolerance varies considerably.

Wegovy vs Mounjaro UK Pricing: Cost Comparison and Best Value

Price is a significant consideration in the Wegovy vs Mounjaro UK decision, as both represent substantial ongoing investments in your health. At Cured Pharmacy, Wegovy starts from £124.99 per month, whilst Mounjaro begins at £124.99, making Wegovy the more affordable option for many patients [5]. These prices include UK prescriber consultation, genuine licensed medication, and discreet next-day delivery.

The cost difference reflects manufacturing, licensing, and market factors rather than necessarily indicating superior efficacy. When evaluating Wegovy vs Mounjaro UK value, consider not just the monthly price but also your individual response, tolerability, and long-term sustainability. Some patients achieve their goals more quickly on one medication, potentially reducing overall treatment duration and cost.

Cured Pharmacy offers transparent upfront pricing with no hidden fees, and new patients can Save £20 on their first order using code Weightlossnew. This represents the cheapest UK price for genuine licensed weight loss injections, backed by our lowest price guarantee and full GPhC registration (9012511). Both treatments require ongoing prescription, so discuss realistic timeframes and total costs with your prescriber during assessment.

Dosing Schedules: Wegovy vs Mounjaro UK Administration Protocols

The dosing protocols in the Wegovy vs Mounjaro UK comparison follow similar gradual escalation patterns to minimise side effects. Wegovy begins at 0.25mg weekly, increasing monthly through 0.5mg, 1mg, and 1.7mg before reaching the 2.4mg maintenance dose at week 17 [1]. Mounjaro starts at 2.5mg weekly, escalating every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, and potentially to 15mg based on individual response and tolerability [2].

Both medications use pre-filled injection pens designed for subcutaneous administration into the abdomen, thigh, or upper arm. The once-weekly schedule offers convenience compared to daily injections, and patients typically inject on the same day each week. If you miss a dose, administration guidelines differ slightly between the two medications, so follow the patient information leaflet carefully or consult our pharmacy team.

The gradual dose escalation is not optional - it's essential for minimising gastrointestinal side effects and allowing your body to adapt to the medication's effects. Never accelerate the dosing schedule without prescriber guidance, as this significantly increases the risk of severe nausea and vomiting that may lead to treatment discontinuation.

Injection Technique for Wegovy vs Mounjaro UK Treatments

Both Wegovy vs Mounjaro UK treatments use similar injection techniques with pre-filled single-dose pens. After attaching a new needle, dialling the dose (pre-set for Wegovy, adjustable for Mounjaro), and selecting an injection site, you'll insert the needle at 90 degrees and press the button until you hear a click. Hold for 6 seconds to ensure full dose delivery. Our clinical team provides comprehensive injection training videos and telephone support to ensure you feel confident administering your treatment safely at home.

Who Should Choose Wegovy vs Mounjaro UK: Clinical Suitability

Determining whether Wegovy vs Mounjaro UK is more suitable requires individualised clinical assessment by a qualified prescriber. Both medications are licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Mounjaro also holds a separate licence for type 2 diabetes management, which may influence prescriber choice for patients with both conditions.

Patients who have previously used GLP-1 medications like Saxenda (liraglutide) or Ozempic (semaglutide for diabetes) may have insights into their tolerability of this drug class, potentially informing the Wegovy vs Mounjaro UK decision. Those who experienced good results but sought additional efficacy might consider Mounjaro's dual mechanism, whilst those satisfied with GLP-1-only therapy may prefer Wegovy's established profile and lower cost.

Contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous severe allergic reaction to semaglutide or tirzepatide, and pregnancy or breastfeeding. Type 1 diabetes, severe gastrointestinal disease, and diabetic retinopathy require careful assessment. Your Cured Pharmacy prescriber will review your complete medical history, current medications, and treatment goals during your confidential online consultation to determine the most appropriate option subject to clinical approval.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
5. Cured Pharmacy. (2025). Weight Loss Treatments Pricing. Cured Pharmacy UK. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.